AbbVie (prior sponsor, Abbott)
Quick facts
Phase 3 pipeline
- ABT-267 · Immunology / Inflammation
ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation. - ABT-333 · Virology / Hepatology
ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication. - ABT-450/r/ABT-267, ABT-333 · Virology / Hepatology
This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes. - ABT-450/ritonavir · Virology / Hepatology
ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels. - ABT-712 · Oncology
ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation. - Leuprolide Acetate 3 Month Depot · Oncology; Endocrinology
Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production. - Open-label Adalimumab · Immunology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - Placebo for ABT-333
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. - Placebo for ABT-450/r/ABT-267 · Hepatology
This is a placebo control with no active pharmacological mechanism. - Placebo (PBO) oral capsules
Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.
Phase 2 pipeline
- ABT-288 High Dose · Diabetes
ABT-288 High Dose is a glucagon receptor antagonist. - ABT-288 Low Dose
- ABT-450 · Infectious Diseases
ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus. - ABT-652 · Immunology / Respiratory
ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. - ABT-652 NSAID
- ABT-806
- ABT-888 · Oncology
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes. - ABT-894 · Multiple Sclerosis, Autoimmune Diseases
ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). - ABT-981
- Adalimumab, current formulation · Immunology
Tumor necrosis factor-alpha inhibitor - Adalimumab, new formulation · Immunology
Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine. - Atrasentan high dose group · Cardiovascular
Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. - Atrasentan low dose group · Cardiovascular
Endothelin receptor antagonist - New formulation adalimumab
Phase 1 pipeline
- ABT-348
- ABT-348 and azacitidine · Oncology
AZA is a hypomethylating agent that targets DNA methyltransferase enzymes. - ABT-348 and carboplatin
- ABT-348 and docetaxel · Oncology
Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division. - ABT-700
- ABT-767
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: